AKBA Market Cap History
Below is a table of the AKBA market cap history going back to 3/20/2014:

Date AKBA Market Cap

Also see: AKBA Shares Outstanding History
and AKBA YTD Return
AKBA Historical Market Cap:
-20.45% CAGR
AKBA Historical Market Cap: +-20.45% CAGR

Mouse over chart for data details
3/20/2014 ...4/30/2022
Akebia Therapeutics is a biopharmaceutical company. Co.'s portfolio includes a late-stage product candidate and a commercial product: Vadadustat, which is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability; and Auryxia® (ferric citrate), which is approved and marketed in the U.S. for two indications which are the control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis or the Hyperphosphatemia Indication, and the treatment of iron deficiency anemia (IDA) in adult patients with CKD not on dialysis or the IDA Indication. We show 33 historical shares outstanding datapoints in our AKBA shares outstanding history coverage, used to compute AKBA market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing AKBA market cap history over the course of time is important for investors interested in comparing AKBA's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of AKBA versus a peer is one thing; comparing AKBA market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like AKBA can fluctuate over the course of history. With this page we aim to empower investors researching AKBA by allowing them to research the AKBA market cap history.
Quotes delayed 20 minutes

Email EnvelopeFree AKBA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Akebia Therapeutics (AKBA) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

AKCA Market Cap History
AKER Market Cap History
AKRO Market Cap History
AKRX Market Cap History
AKUS Market Cap History
AKYA Market Cap History
ALBO Market Cap History
ALC Market Cap History
ALDR Market Cap History
ALDX Market Cap History
More Healthcare companies »


AKBA Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.